Impact of an institutional guideline on post-discharge follow-up for neonatal hyperbilirubinaemia: a before-and-after cohort study Authors: Tapanee Pipatkullachart, Kotchakorn Lakornpol, Kanokwan Aeimcharnbanchong Published: 2026 ABSTRACT BackgroundNeonatal hyperbilirubinaemia requires timely post-discharge follow-up to prevent bilirubin-induced neurological injury while minimising unnecessary healthcare utilisation. Implementation of the 2022 American Academy of Pediatrics (AAP) guideline at our institution was associated with increased follow-up visits and variability in clinical practice, particularly among low-risk infants. To optimise resource utilisation while maintaining patient safety, we developed an institutional guideline integrating the 2021 Bhutani nomogram with the 2022 AAP guideline, incorporating selective follow-up criteria and simplified phototherapy threshold tools. This study evaluated the impact of the institutional guideline on follow-up practices and neonatal hyperbilirubinemia management outcomes.MethodsWe conducted a retrospective–prospective before-and-after cohort study at Panyananthaphikkhu Chonprathan Medical Center, Thailand, comparing outcomes before (June–November 2024) and after (December 2024–May 2025) guideline implementation. Eligible newborns were ≥ 35 weeks’ gestation and discharged without phototherapy. Categorical variables were compared using χ2 or Fisher’s exact tests, and continuous variables using Student’s t-test. Clinical outcomes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs). All tests were two-sided, with p < 0.05 considered statistically significant. Statistical analyses were performed using Stata version 19. The primary outcome was the proportion scheduled for post-discharge follow-up, and secondary outcome was hospital readmission for hyperbilirubinaemia.ResultsA total of 274 neonates were included (137 pre-implementation, 137 post-implementation). Post-discharge follow-up was reduced after guideline implementation (34.3% vs 49.6%; RR 0.69, 95% CI 0.52–0.92; p 0.010). Readmission rates were similar between groups (3.6% vs 2.9%; RR 1.24, 95% CI 0.33–4.55; p = 1.00). All readmitted infants required phototherapy and no cases of exchange transfusion occurred.ConclusionsImplementation of an institutional follow-up guideline reduced post-discharge follow-up without any preliminary signal of harm. Local adaptation of international guidelines may improve efficiency and standardisation of care, particularly in resource-constrained settings. Background Neonatal hyperbilirubinaemia is common and requires timely and appropriate post-discharge follow-up to prevent bilirubin-induced neurological injury [1, 2] while minimising unnecessary healthcare utilisation [3]. Earlier American Academy of Pediatrics (AAP) guidelines (2004 and 2009) [1, 4] stratified risk using the Bhutani nomogram [5]. An updated Bhutani nomogram, introduced in 2021, was derived from a substantially larger dataset [6]. These approaches rely on postnatal age and bilirubin concentration but do not explicitly integrate gestational age or neurotoxicity risk factors. In contrast, the 2022 AAP guideline introduced a threshold-based strategy, recommending follow-up according to the difference between the measured total serum bilirubin level and the phototherapy threshold, incorporating gestational age and risk factors to support individualised care [7]. Following implementation of the 2022 American Academy of Pediatrics hyperbilirubinaemia guideline, our institution observed increased post-discharge follow-up visits and variability in clinical practice. A local root-cause analysis identified several contributing factors. First, follow-up recommendations were expanded to include all infants discharged before 72 h of age, including those previously classified as low risk, particularly those in the low-risk zone on the 2021 Bhutani nomogram. This change substantially increased the number of newborns requiring outpatient reassessment after discharge. Second, for infants discharged at or after 72 h of age, the guideline recommends that follow-up decisions incorporate multiple clinical factors, including physical examination findings, risk factors for developing hyperbilirubinaemia, neurotoxicity risk factors, feeding adequacy, weight trajectory, and family support. Consequently, clinical judgement played a major role in determining the need for follow-up, contributing to inter-provider variability in follow-up decisions. Additional challenges arose from interpretation of the gestational age–specific phototherapy threshold charts introduced in the 2022 AAP guideline. The complexity of the AAP 2022 phototherapy threshold graphs, which include multiple gestational-age–specific curves, along with uncertainty in assigning the appropriate neurotoxicity risk category prior to definitive classification of hyperbilirubinaemia, may have contributed to variability in phototherapy-related decision-making. To address these limitations while maintaining patient safety, The institutional implementation components focused on limiting routine follow-up among infants discharged before 72 h of age who were classified as low risk, specifically those with total serum bilirubin (TSB) levels below the 40th percentile on the 2021 Bhutani nomogram or with a difference of ≥ 5.5 mg/dL between the phototherapy threshold and TSB in the absence of additional risk factors for significant hyperbilirubinaemia. They also included implementing a stepwise neonatal assessment pathway with clearly defined criteria for identifying infants requiring follow-up within the framework of the 2022 AAP recommendations. In addition, simplified gestational-age–specific phototherapy threshold tables were developed, replacing the complex, multiple-line AAP graph-based tools with consolidated, easy-to-read tabular formats, to improve interpretation and reduce variability among healthcare providers. This study aimed to evaluate the impact of implementing the institutional guideline on post-discharge follow-up practices and neonatal hyperbilirubinaemia management outcomes. Methods Study design and setting We conducted a combined retrospective and prospective cohort study at PCMC, a tertiary care hospital, to compare neonatal outcomes before and after the implementation of an institutional guideline for post-discharge management of neonatal hyperbilirubinaemia. In the pre-implementation cohort, post-discharge follow-up was conducted according to the 2022 AAP guideline. In the post-implementation cohort, a simplified institutional guideline was used. Study Population We included all newborns with a gestational age ≥ 35 weeks born at PCMC between 1 June 2024 and 31 May 2025. Infants were assigned to cohorts based on discharge date: pre-implementation (1 June–30 November 2024) and post-implementation (1 December 2024–31 May 2025). Eligibility Criteria Eligible participants were newborns ≥ 35 weeks’ gestation who had a TSB measurement within 72 h of birth and were discharged without prior phototherapy. Exclusion criteria Neonates transferred to another hospital, those with hospitalization beyond 48 h of life (including admission to the neonatal intensive care unit or special care nursery), those diagnosed with liver or metabolic disorders affecting bilirubin metabolism, and those unable to complete follow-up were excluded. Withdrawal Criteria Participants with incomplete follow-up to one month of age were excluded from analysis. Study procedures For the retrospective cohort, a waiver of informed consent was granted, and approval was obtained from the hospital director following ethics approval. For the prospective cohort, written informed consent was obtained from parents or legal guardians prior to data collection. Eligible participants were assessed for post-discharge follow-up using an institutional guideline for neonatal hyperbilirubinaemia. The institutional guideline was developed by a multidisciplinary team consisting of neonatologists, pediatricians, and pediatric interns responsible for newborn care at our institution. The development process involved multiple meetings to review the 2022 AAP recommendations, identify local implementation challenges, and achieve consensus regarding follow-up criteria and phototherapy assessment practices before formal adoption into the Department of Pediatrics clinical practice protocol at PCMC. Prior to implementation, clinicians received orientation sessions and practical training regarding use of the institutional guideline. Adherence to the guideline was monitored through periodic review of medical records and follow-up documentation throughout the study period. The institutional guideline integrated the 2021 Bhutani nomogram with the 2022 AAP hyperbilirubinaemia guideline and is illustrated in Fig. 1, as described below. Fig. 1Institutional Guideline Institutional Guideline Institutional guideline Step 1: Initial assessment At the time of evaluation, postnatal age (in hours) was recorded, and hematocrit (Hct) along with TSB was measured. The measured bilirubin value was then compared with age- and gestational age–specific phototherapy thresholds (mg/dL), derived from the 2022 AAP guideline for infants with neurotoxicity risk factors, as shown in Table 1 within Fig. 1. Step 2: Determination of follow-up requirement The need for follow-up bilirubin testing was determined using Table 2 within Fig. 1, based on the updated 2021 Bhutani nomogram. Infants with TSB levels below the 40th percentile (low-risk zone) on the 2021 Bhutani nomogram were classified as low risk and did not require routine follow-up, whereas infants with TSB levels at or above the 40th percentile required follow-up. The timing of follow-up was guided by Table 3 within Fig. 1, adapted from the 2022 AAP guideline. Recommendations were based on the difference between the phototherapy threshold and the measured TSB (mg/dL), as well as the presence of risk factors for significant hyperbilirubinaemia, including gestational age 35–36 6/7 weeks; hemolytic risk (e.g., G6PD deficiency); significant bruising or hematoma; macrosomia in infants of diabetic mothers; exclusive breastfeeding with ≥ 7% weight loss; a family history of phototherapy or exchange transfusion; and rapid bilirubin rise (> 0.3 mg/dL/hour in the first 24 h or > 0.2 mg/dL/hour thereafter). Step 3: Neonatal management decision Infants were classified into two management pathways: (1) no follow-up required or (2) follow-up required. For those requiring follow-up, the timing of repeat bilirubin assessment was specified in hours based on risk stratification and clinical judgment. Difference Between the 2022 AAP guideline and the institutional guideline Compared with the 2022 AAP guideline, our institutional guideline adopted a more selective and standardised approach to post-discharge follow-up. Infants discharged before 72 h of age were not routinely scheduled for follow-up if their total serum bilirubin (TSB) level was below the 40th percentile on the 2021 Bhutani nomogram or if the difference between the phototherapy threshold and TSB was ≥ 5.5 mg/dL in the absence of additional risk factors for significant hyperbilirubinaemia. In addition, the institutional protocol introduced a structured stepwise neonatal assessment pathway with clearly defined follow-up criteria and simplified gestational age–specific phototherapy threshold tables to reduce inter-provider variability in clinical decision-making while remaining aligned with the overall framework of the 2022 AAP recommendations. Post-discharge follow-up All participants were followed for one month to monitor for readmission for phototherapy or exchange transfusion. Follow-up data were obtained from electronic medical records (EMRs); when data were incomplete or unavailable, parents were contacted by telephone to obtain additional information on the infant’s health status and any complications. Data collection Clinical data were extracted from electronic medical records, including maternal characteristics (age, gravidity, parity, blood group, and mode of delivery) and neonatal characteristics (gestational age, birth weight, bilirubin measurements, and risk factors for hyperbilirubinaemia). Data on planned post-discharge follow-up and hospital readmissions were also collected. Outcomes The primary outcome was the proportion of infants scheduled for post-discharge follow-up for neonatal jaundice in the pre- and post-implementation periods. Secondary outcomes included hospital readmission for hyperbilirubinaemia and the incidence of exchange transfusion. Statistical analysis Sample size was calculated based on detecting a difference in the proportion of neonates requiring post-discharge follow-up between groups. Assuming a two-sided alpha of 0.05, 80% power, and an expected absolute difference of approximately 15% between groups based on a pilot study, the minimum required sample size was estimated to be approximately 120 neonates per group. To account for potential loss to follow-up, the sample size was inflated, resulting in a final target sample size of 137 neonates per group. Categorical variables are presented as frequencies and percentages and were compared using the χ2 test or Fisher’s exact test, as appropriate. Continuous variables are presented as means and standard deviations (SD) and were compared using Student’s t-test after assessment of distributional assumptions. Comparisons were made between the pre-guideline and post-guideline groups. For clinical outcomes, effect estimates are presented as risk ratios (RRs) with 95% confidence intervals (CIs). All tests were two-sided, and a p-value < 0.05 was considered statistically significant. Analyses were performed using Stata version 19 (StataCorp, College Station, TX, USA). Results A total of 274 neonates were included in the analysis, comprising 137 infants in the pre-guideline group and 137 infants in the post-guideline group. Baseline demographic and clinical characteristics are presented in Table 1. Baseline neonatal and maternal characteristics were comparable between the two groups.Table 1Baseline characteristics of pre- and post-guideline groupsDemographic dataPre-guideline(N = 137)Post-guideline(N = 137)P-valueGestational age (weeks), mean ± SD38.4 ± 1.038.3 ± 1.20.547Birth weight (grams), mean ± SD3,058.6 ± 377.23,073.2 ± 351.50.741Sex, N (%)1.000Male70 (51.1)70 (51.1)Female67 (48.9)67 (48.9)Total serum bilirubin (mg/dL), mean ± SD8.8 ± 1.58.6 ± 1.10.209Age at total serum bilirubin (hours), mean ± SD49.5 ± 4.249.2 ± 3.20.503Maternal age (years), mean ± SD30.0 ± 5.529.1 ± 5.70.205Gravidity, Median (IQR 1, 3)2 (1,3)2 (1,3)1.000Parity, Median (IQR 1, 3)1 (0,1)1 (0,1)1.000Maternal blood group ABO, N (%)0.807A36 (26.3)32 (23.4)B52 (38.0)54 (39.4)AB5 (3.6)8 (5.8)O44 (32.1)43 (31.4)Maternal blood group Rh, N (%)1.000Rh + 136 (99.3)137(100)Rh-1 (0.7)0 (0)Mode of delivery, N (%)0.545Normal labor69 (50.4)74 (54)Cesarean section68 (49.6)63 (46)Abbreviations: SD standard deviation, IQR interquartilerange Table 1Baseline characteristics of pre- and post-guideline groupsDemographic dataPre-guideline(N = 137)Post-guideline(N = 137)P-valueGestational age (weeks), mean ± SD38.4 ± 1.038.3 ± 1.20.547Birth weight (grams), mean ± SD3,058.6 ± 377.23,073.2 ± 351.50.741Sex, N (%)1.000Male70 (51.1)70 (51.1)Female67 (48.9)67 (48.9)Total serum bilirubin (mg/dL), mean ± SD8.8 ± 1.58.6 ± 1.10.209Age at total serum bilirubin (hours), mean ± SD49.5 ± 4.249.2 ± 3.20.503Maternal age (years), mean ± SD30.0 ± 5.529.1 ± 5.70.205Gravidity, Median (IQR 1, 3)2 (1,3)2 (1,3)1.000Parity, Median (IQR 1, 3)1 (0,1)1 (0,1)1.000Maternal blood group ABO, N (%)0.807A36 (26.3)32 (23.4)B52 (38.0)54 (39.4)AB5 (3.6)8 (5.8)O44 (32.1)43 (31.4)Maternal blood group Rh, N (%)1.000Rh + 136 (99.3)137(100)Rh-1 (0.7)0 (0)Mode of delivery, N (%)0.545Normal labor69 (50.4)74 (54)Cesarean section68 (49.6)63 (46)Abbreviations: SD standard deviation, IQR interquartilerange Baseline characteristics of pre- and post-guideline groups Abbreviations: SD standard deviation, IQR interquartilerange Clinical outcomes are summarised in Table 2. The primary outcome, the proportion of neonates requiring post-discharge follow-up, was significantly lower in the post-guideline group than in the pre-guideline group (34.3% vs 49.6%), corresponding to a risk ratio of 0.69 (95% CI 0.52–0.92; p = 0.010).Table 2Clinical outcomes pre- and post-guideline implementationClinical outcomesPre-guideline (N = 137)Post-guideline (N = 137)RR(95% CI)P-valueFollow-up required, N (%)68 (49.6)47 (34.3)0.69 (0.52–0.92)0.010Readmission, N (%)4 (2.9)5 (3.6)1.24 (0.33–4.55)1.00Abbreviations: RR risk ratio, CI confidence interval Table 2Clinical outcomes pre- and post-guideline implementationClinical outcomesPre-guideline (N = 137)Post-guideline (N = 137)RR(95% CI)P-valueFollow-up required, N (%)68 (49.6)47 (34.3)0.69 (0.52–0.92)0.010Readmission, N (%)4 (2.9)5 (3.6)1.24 (0.33–4.55)1.00Abbreviations: RR risk ratio, CI confidence interval Clinical outcomes pre- and post-guideline implementation Abbreviations: RR risk ratio, CI confidence interval For secondary outcomes, hospital readmission occurred in 5/137 (3.6%) neonates in the post-guideline group and 4/137 (2.9%) in the pre-guideline group, with no statistically significant difference between groups (RR 1.24, 95% CI 0.33–4.55; p = 1.00). All readmitted neonates required phototherapy. No cases of exchange transfusion were observed in either group. Loss to follow-up was also not significantly different between groups (2.2% vs 0.73%; p = 0.62). Discussion Implementation of the institutional guideline was associated with a significant reduction in post-discharge follow-up without an increase in hospital readmissions. No cases of exchange transfusion were observed. Although several previous studies, including data from our institution, have demonstrated a reduction in phototherapy rates following implementation of the 2022 AAP guideline [8–12], evidence regarding its impact on post-discharge follow-up practices remains limited. To date, few studies have evaluated the effects of the 2022 AAP recommendations on follow-up practices in real-world clinical settings. In resource-limited settings, follow-up for neonatal jaundice is predominantly conducted through scheduled hospital visits, in contrast to high-income settings where alternative strategies—such as smartphone-based screening, home visit programmes, and home phototherapy—are more widely available [13, 14]. Limited access to equipment and trained healthcare personnel in these settings necessitates reliance on hospital-based follow-up. However, this approach may lead to overuse of healthcare resources and impose additional burdens on infants, families, and health systems [3]. Conversely, inadequate follow-up may result in acute bilirubin encephalopathy and, in severe cases, long-term complications such as kernicterus [1, 2]. Therefore, optimising post-discharge follow-up strategies is essential to ensure patient safety and should be tailored to the specific clinical context of each healthcare setting [15–17]. In this study, 49.6% of neonates who did not receive phototherapy were scheduled for post-discharge follow-up under the 2022 AAP guideline, comparable to 74.4% reported in a Thai cohort [11]. Implementation of a tailored institutional guideline was associated with a meaningful reduction in follow-up rates without any preliminary signal of harm. Several factors may account for this finding. The AAP recommendation for follow-up within three days for infants discharged before 72 h, even when TSB levels are ≥ 5.5 mg/dL below treatment thresholds and in the absence of risk factors, may promote overutilization in low-risk populations. Consistent with this, none of these infants in our cohort subsequently required phototherapy. In addition, the complexity of gestational age–specific phototherapy charts and ambiguity in selecting between graphs for infants with versus without neurotoxicity risk factors, particularly when the underlying cause of hyperbilirubinaemia has not yet been determined, may contribute to uncertainty in clinical decision-making. Following implementation, hospital readmission rates remained similar between groups at approximately 6%, consistent with previous reports from Thailand [18, 19]. These findings suggest that reducing follow-up intensity in selected populations was not associated with an observed increase in readmission. Overall, these results suggest that a simplified, locally adapted follow-up strategy may improve efficiency and standardisation of care in resource-constrained settings. Adaptation of international guidelines to local contexts may enhance both care delivery and resource utilisation. Strengths and limitations A key strength of this study is the use of real-world data from the pre- and post-implementation periods within the same institution, allowing evaluation of practice changes in a consistent clinical setting. The study also evaluated the impact of reduced scheduled follow-up visits on readmissions for neonatal hyperbilirubinaemia within one month after discharge. Limitations include the single-centre design, which may limit generalisability, and the relatively small sample size, which precluded definitive conclusions regarding the safety of the institutional guideline for rare adverse outcomes. Multicentre studies with larger sample sizes are warranted to confirm these findings. Conclusions Implementation of an institutional follow-up guideline reduced post-discharge follow-up without any preliminary signal of harm. Local adaptation of international guidelines may improve efficiency and standardisation of care, particularly in resource-constrained settings.